Breast cancer is the most common cancer among women worldwide. Yet most cancer diagnostics are built for patients who have already entered the healthcare system — the much larger population of women who are never routinely screened is left behind.
women worldwide lack access to regular cancer screening.
Breast cancer is the most common cancer in women worldwide — and the population most in need of screening is the one least likely to have access to it.
Harae Dx is building the world’s first globally deployable diagnostic platform for early cancer detection — starting with breast cancer and expanding to pan-cancer.
Five complementary biomarkers across critical biological pathways, interpreted with explainable AI.
Portable, easy-to-use system for decentralized deployment in clinics, hospitals, pharmacies, and community settings.
Built to continuously learn and improve with more data, and to extend to multiple cancer indications.
Designed for accessible, affordable cancer screening across both developed and emerging markets.
Built on nearly two decades of biomarker research and clinical development leadership.
Key protein biomarkers linked to cancer biology identified through early research at a national research laboratory.
Clinical validation of the five-biomarker panel advanced with an external clinical partner.
Harae Dx integrates biology, explainable AI, and point-of-care hardware into one platform.
The global cancer diagnostics market is large and growing quickly, driven by the rise of liquid biopsy and portable testing.
Global cancer diagnostics market
Breast cancer detection segment
Non-invasive, rapid cancer screening to support better treatment decisions.
Improving healthcare access in underserved areas globally.
A team with deep IVD experience, spanning product, regulatory, and finance — several of whom have taken diagnostics companies through prior exits.
